38875-53-5

Usage

Uses

Used in Pharmaceutical Industry:
2,3-Diamino-5-bromopyridine is used as a key intermediate in the synthesis of various heterocyclic compounds, which are important for the development of pharmaceuticals with diverse therapeutic applications. Its unique structure allows for the formation of multiple bonds and functional groups, making it a valuable component in the creation of new drug candidates.
Used in Chemical Research:
In the field of chemical research, 2,3-Diamino-5-bromopyridine serves as a valuable precursor for the preparation of complex organic molecules and the study of their properties. Its reactivity and structural features make it an ideal candidate for exploring new reaction pathways and understanding the fundamental principles of organic chemistry.
Specific Applications:
2,3-Diamino-5-bromopyridine is used as a building block for the preparation of the following heterocyclic compounds:
6-Bromoimidazo[1,2-a]pyridine: 2,3-Diamino-5-bromopyridine may have potential applications in medicinal chemistry, particularly as a scaffold for the development of new drugs with specific biological activities.
6-Bromo-3-(tetrahydro-2H-pyran-2-yl)-3H-imidazo[4,5-b]pyridine: 2,3-Diamino-5-bromopyridine may find use in the development of new pharmaceutical agents, particularly those targeting specific receptors or enzymes, due to its unique structure and potential for further functionalization.

InChI:InChI=1/C5H6BrN3/c6-3-1-4(7)5(8)9-2-3/h1-2H,7H2,(H2,8,9)/p+1

Upstream product

• 6945-68-2 5-bromo-3-nitro-pyridin-2-ylamine 
• 1003711-13-4 6-amino-5-nitronicotinonitrile 
• 7440-44-0 pyrographite 

Downstream Products

• 28279-49-4 6-bromo-1H-imidazo[4,5-b]pyridine 
• 93752-20-6 6-bromo-1H-imidazo[4,5-b]pyridine-2(3H)-thione 
• 148038-83-9 6-bromo-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 452-58-4 2,3-Diaminopyridine 
• 155630-03-8 2-amino-5-bromo-3-(1-pyrrolyl)pyridine 
• 42869-47-6 6-bromo-2-methyl-1H-imidazo[4,5-b]pyridine 
• 65147-89-9 6-bromo-2-phenyl-1H-imidazo<4,5-b>pyridine 
• 113311-87-8 6-Bromo-2-(2,5-dimethoxy-phenyl)-3H-imidazo[4,5-b]pyridine 
• 52333-43-4 7-bromo-2,3-dimethylpyrido<2,3-b>pyrazine 
• 38870-31-4 7-bromo-2,3-diphenyl-5-azaquinoxaline 
• 68175-12-2 6-Brom-2-ethyl-1H-imidazo pyridin 
• 56291-49-7 2-benzyl-6-bromo-1H-imidazo<4,5-b>pyridine 
• 258834-82-1 5-bromo-2,3-bis[di-(4-methoxybenzyl)amino]pyridine 
• 172648-19-0 (6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)methanol 

Relevant academic research and scientific papers

Synthesis, biological properties and structural study of new halogenated azolo[4,5-b]pyridines as inhibitors of CK2 kinase

The new halogenated 1H-triazolo[4,5-b]pyridines and 1H-imidazo[4,5-b]pyridines were synthesised as analogues of known CK2 inhibitors: 4,5,6,7-tetrabromo-1H-benzotriazole (TBBt) and 4,5,6,7-tetrabromo-1H-benzimidazole (TBBi). Their influence on the activity of recombinant human CK2α, CK2α’ and PIM1 kinases was determined. The most active inhibitors were di- and trihalogenated 1H-triazolo[4,5-b]pyridines (4a, 5a and 10a) with IC50 values 2.56, 3.82 and 3.26 μM respectively for CK2α. Furthermore, effect on viability of cancer cell lines MCF-7 (human breast adenocarcinoma) and CCRF-CEM (T lymphoblast leukemia) of all final compounds was evaluated. Finally, three crystal structures of complexes of CK2α1-335 with inhibitors 4a, 5a and 10a were obtained. In addition, new protocol was used to obtain high-resolution crystal structures of CK2α’Cys336Ser in complex with four inhibitors (4a, 5a, 5b, 10a).

Mild and efficient addition of carbon nucleophiles to condensed pyridines: influence of structure and limits of applicability

[Figure not available: see fulltext.] A number of azolo- and azinopyridines with varying substituents and annulated heterocycles were synthesized and examined in dearomatization reactions with carbon nucleophiles. Depending on the structure, the resulting covalent σ-adducts were formed either under basefree conditions or in Et3N-promoted process to give functionalized condensed dihydropyridines. Quantum-chemical calculations of the global electrophilicity index derived from FMO energies of azolopyridine series were performed to explain reactivity toward neutral and anionic C-nucleophiles. These values may be useful for qualitative prediction of particular reactivity pattern.

Benzimidazole derivatives, their preparation and their application in medicine and pharmacology (by machine translation)

The invention relates to a new control or inhibit indocyanine 2, 3 - dioxygenase (IDO) activity of the benzimidazole derivatives, their preparation and their application in medicine and pharmacology. Specifically, the invention relates to a compound of general formula (I) compound of formula and its pharmaceutically acceptable salt, containing the compound or its pharmaceutically acceptable salt of the pharmaceutical composition, the use of the compound or its pharmaceutically acceptable salts for treating and/or preventing the relevance of the IDO-mediated disease, especially a tumor of the method and the compound or its pharmaceutically acceptable salts thereof. The invention also relates to the compound or its pharmaceutically acceptable salt or containing the compound or its pharmaceutically acceptable salts for the preparation of a pharmaceutical composition for treating and/or preventing the relevance of the IDO-mediated disease, in particular of the use of the drug in the tumor. Wherein the general formula (I) of each substituent is as defined in the specification. (by machine translation)

Cobalt-based nanoparticles prepared from MOF-carbon templates as efficient hydrogenation catalysts

The development of efficient and selective nanostructured catalysts for industrially relevant hydrogenation reactions continues to be an actual goal of chemical research. In particular, the hydrogenation of nitriles and nitroarenes is of importance for the production of primary amines, which constitute essential feedstocks and key intermediates for advanced chemicals, life science molecules and materials. Herein, we report the preparation of graphene shell encapsulated Co3O4- and Co-nanoparticles supported on carbon by the template synthesis of cobalt-terephthalic acid MOF on carbon and subsequent pyrolysis. The resulting nanoparticles create stable and reusable catalysts for selective hydrogenation of functionalized and structurally diverse aromatic, heterocyclic and aliphatic nitriles, and as well as nitro compounds to primary amines (>65 examples). The synthetic and practical utility of this novel non-noble metal-based hydrogenation protocol is demonstrated by upscaling several reactions to multigram-scale and recycling of the catalyst.

Fragment-based discovery of new highly substituted 1H-pyrrolo[2,3-b]- and 3H-imidazolo[4,5-b]-pyridines as focal adhesion kinase inhibitors

Focal adhesion kinase (FAK) is considered as an attractive target for oncology, and small-molecule inhibitors are reported to be in clinical testing. In a surface plasmon resonance (SPR)-mediated fragment screening campaign, we discovered bicyclic scaffolds like 1H-pyrazolo[3,4-d]pyrimidines binding to the hinge region of FAK. By an accelerated knowledge-based fragment growing approach, essential pharmacophores were added. The establishment of highly substituted unprecedented 1H-pyrrolo[2,3-b]pyridine derivatizations provided compounds with submicromolar cellular FAK inhibition potential. The combination of substituents on the bicyclic templates and the nature of the core structure itself have a significant impact on the compounds FAK selectivity. Structural analysis revealed that the appropriately substituted pyrrolo[2,3-b]pyridine induced a rare helical DFG-loop conformation. The discovered synthetic route to introduce three different substituents independently paves the way for versatile applications of the 7-azaindole core.

Nanoscale Fe2O3-based catalysts for selective hydrogenation of nitroarenes to anilines

Production of anilines - key intermediates for the fine chemical, agrochemical, and pharmaceutical industries - relies on precious metal catalysts that selectively hydrogenate aryl nitro groups in the presence of other easily reducible functionalities. Herein, we report convenient and stable iron oxide (Fe2O3) - based catalysts as a more earth-abundant alternative for this transformation. Pyrolysis of iron-phenanthroline complexes on carbon furnishes a unique structure in which the active Fe2O 3 particles are surrounded by a nitrogen-doped carbon layer. Highly selective hydrogenation of numerous structurally diverse nitroarenes (more than 80 examples) proceeded in good to excellent yield under industrially viable conditions.

1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER

The invention provides a family of 1,4-benzodiazepinone compounds and methods for their use as therapeutic agents in treating cancer. Pharmaceutical compositions and methods of making the 1,4-benzodiazepinone compounds are provided.

Methods for Chk2 inhibitor patient selection

The present invention contemplates a method to identify subjects that either have a tumor, or are at risk for tumor development, that are responsive to various inhibitors of an activated-Chk2 protein. Such Chk2 inhibitors may comprise a benzimidazole core structure, and derivatives thereof. Other Chk2 inhibitors may comprise nucleic acids, such as silencing interference RNA's specific for a Chk2 expression. Other Chk2 inhibitors may comprises proteins, such as antibodies. For example, the present invention contemplates that when a Chk2 inhibitor is administered during, or after, ionizing radiation tumor cell apoptosis is increased.

Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors

A series of four bicyclic cores were prepared and evaluated as cyclin-dependent kinase-2 (CDK2) inhibitors. From the in-vitro and cell-based analysis, the pyrazolo[1,5-a]pyrimidine core (represented by 9) emerged as the superior core for further elaboration in the identification of novel CDK2 inhibitors.

BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE

The present invention provides a heterocyclic compound having potent tyrosine kinase-inhibiting activity represented by formula: (wherein, R1b is a C6-10 aryl group which has substituent(s), and the like; Ta is a single bond, a C1-6 alkyl group, -CH2O-, and the like; X and Y are the same or different, and each is a nitrogen atom which may have substituent(s), and the like; the broken line is a single bond or a double bond; Za is a nitrogen atom or CH; W is a single bond, an oxygen atom, and the like; Q is a C6-10 aryl group which may have substituent(s) or an aromatic heterocyclic group which may have substituent(s)); or a salt thereof and a pharmaceutical composition comprising thereof.